Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT PR Newswire SEOUL, South Korea, Nov. 14, 2023 - Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea , Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3D Breast...